Vertex Pharmaceuticals (Germany) Price Prediction
| VX1 Stock | EUR 429.45 5.60 1.32% |
Oversold Vs Overbought
63
Oversold | Overbought |
Using Vertex Pharmaceuticals hype-based prediction, you can estimate the value of Vertex Pharmaceuticals Incorporated from the perspective of Vertex Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Vertex Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Vertex because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Vertex Pharmaceuticals after-hype prediction price | EUR 429.45 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Vertex |
Vertex Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Vertex Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Vertex Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Vertex Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Vertex Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Vertex Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Vertex Pharmaceuticals' historical news coverage. Vertex Pharmaceuticals' after-hype downside and upside margins for the prediction period are 427.56 and 431.34, respectively. We have considered Vertex Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Vertex Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Vertex Pharmaceuticals is based on 3 months time horizon.
Vertex Pharmaceuticals Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Vertex Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vertex Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Vertex Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.01 | 1.87 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Any time |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
429.45 | 429.45 | 0.00 |
|
Vertex Pharmaceuticals Hype Timeline
Vertex Pharmaceuticals is at this time traded for 429.45on Frankfurt Exchange of Germany. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Vertex is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is estimated to be very small, whereas the daily expected return is at this time at 0.01%. %. The volatility of related hype on Vertex Pharmaceuticals is about 0.0%, with the expected price after the next announcement by competition of 429.45. About 96.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.42. Vertex Pharmaceuticals recorded earning per share (EPS) of 11.89. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000. Assuming the 90 days horizon the next estimated press release will be any time. Check out Vertex Pharmaceuticals Basic Forecasting Models to cross-verify your projections. For more detail on how to invest in Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.Vertex Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Vertex Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Vertex Pharmaceuticals' future price movements. Getting to know how Vertex Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Vertex Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| WCLA | Calibre Mining Corp | 0.00 | 0 per month | 2.43 | (0.02) | 4.11 | (4.09) | 13.59 | |
| M8Z | MAGNUM MINING EXP | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 85S | Science Applications International | 0.00 | 0 per month | 2.82 | (0.02) | 2.61 | (2.08) | 21.06 | |
| P4Q | Perseus Mining Limited | 0.00 | 0 per month | 2.25 | 0 | 3.85 | (3.61) | 14.33 | |
| BJI | DATANG INTL POW | 0.00 | 0 per month | 0.00 | (0.04) | 6.25 | (5.88) | 21.11 | |
| 20Y | Data3 Limited | 0.00 | 0 per month | 1.99 | (0.06) | 3.18 | (3.00) | 11.26 | |
| FJZ | Zijin Mining Group | 0.00 | 0 per month | 4.01 | 0 | 6.75 | (7.57) | 18.51 | |
| BJI | Datang International Power | 0.00 | 0 per month | 2.58 | (0.02) | 6.25 | (5.88) | 21.11 |
Vertex Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Vertex price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Vertex using various technical indicators. When you analyze Vertex charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Vertex Pharmaceuticals Predictive Indicators
The successful prediction of Vertex Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Vertex Pharmaceuticals Incorporated, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Vertex Pharmaceuticals based on analysis of Vertex Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Vertex Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Vertex Pharmaceuticals's related companies.
Story Coverage note for Vertex Pharmaceuticals
The number of cover stories for Vertex Pharmaceuticals depends on current market conditions and Vertex Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Vertex Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Vertex Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Vertex Pharmaceuticals Short Properties
Vertex Pharmaceuticals' future price predictability will typically decrease when Vertex Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Vertex Pharmaceuticals Incorporated often depends not only on the future outlook of the potential Vertex Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vertex Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 257 M |
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |